This is a StreetInsider.com Premium Only Page

Karyopharm Therapeutics (KPTI) – Analyst EPS View

Apr 10, 2018 07:27 AM Karyopharm Therapeutics (KPTI) PT Raised to $20 at JPMorgan; 'Favorable Reward/Risk Forecast into End-April Topline STORM Data'

Apr 5, 2017 08:55 AM Wedbush Reiterates Outperform Rating and $14 PT on Karyopharm Therapeutics (KPTI); 'Selinexor Durable Responses in DLBCL Supports Accelerated Approval Potential'

Apr 4, 2017 04:46 PM

Mar 17, 2017 07:59 AM

Aug 18, 2016 07:40 AM

Dec 22, 2015 08:48 AM

Aug 11, 2015 07:58 AM

Oct 6, 2014 04:33 PM